Waldencast has acquired Novaestiq, marking a pivotal step in positioning Obagi Medical as an industry leader in integrated skincare and aesthetic solutions.WHO: Saypha is distinguished by its proprietary technology, which delivers advanced hyaluronic acid (HA) treatments through a stable 3D matrix designed to provide natural-looking results with optimally balanced gel characteristics. This technology powers a portfolio of clinically proven products that lead in multiple performance categories, including high HA content at injection, ideal gel distribution, and consistent injection force and swelling behavior. Saypha, a product of Croma-Pharma GmbH, is developed and manufactured in Austria and marketed in over 80 countries, leveraging 40 years of expertise in HA-based treatments with more than 110 million syringes produced.Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the business combination with Obagi Medical and Milk Makeup.Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+years of experience.